PRME | tickerfilter.com

Fundamental analysis

34%

Profitability 35%

Dept financing 34%

Liquidity 50%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

1.00%

1 Month

17.39%

3 Months

-5.15%

6 Months

-0.74%

1 Year

113.16%

2 Year

-49.56%

Key data

Stock price

$4.05

P/E Ratio

N/A

DAY RANGE

$4.00 - $4.40

EPS

-$1.25

52 WEEK RANGE

$1.11 - $6.94

52 WEEK CHANGE

$112.04

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

180.552 M

DIVIDEND

$0.00

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-09-2025

BETA

3.04

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,872,927

AVERAGE 30 VOLUME

$2,800,855

Company detail

CEO: Keith M. Gottesdiener
Region: US
Website: primemedicine.com
Employees: 0
IPO year: 2015

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. We were incorporated under the laws of the State of Delaware in September 2019 under the name Prime Medicine, Inc. Our principal executive offices are located at 21 Erie Street, Cambridge, MA.

PRME - Prime Medicine, Inc.